Antitrust Antitrust

US FTC to scrutinize drug patents listed in FDA Orange Book; improper listings may be litigated, official warns

By Khushita Vasant
  • 29 Nov 2023 01:22
  • 29 Nov 2023 01:52
Pharmaceutical companies were put on notice today by a senior Federal Trade Commission enforcer over improperly listed patents that could chill generic drug competition in the US, with a warning that the agency may potentially litigate against such anticompetitive conduct.
“The FTC intends to scrutinize patents listed in the Orange

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Khushita Vasant

Chief Antitrust Correspondent, US


Khushita covers US antitrust enforcement and litigation for MLex. A former Brussels hand, she wrote about about antitrust & mergers for the Policy and Regulatory Report (PaRR), she has covered the EU's actions against Google, Apple, Facebook and Amazon to name a few. Khushita specialises in tech and patent policy coverage which featured in the Concurrences Antitrust Writing Awards. Previously as a financial journalist for The Wall Street Journal and Dow Jones Newswires, she wrote about monetary policy and the bond and currency markets. Khushita studied journalism at Mumbai University, and received an Erasmus Mundus scholarship for a masters from universities in Germany and Austria.

Discover MLex

Stay on top of global regulatory developments

Latest News